Skip to main content

Radicava ORS FDA Approval History

FDA Approved: Yes (First approved May 12, 2022)
Brand name: Radicava ORS
Generic name: edaravone
Dosage form: Oral Suspension
Company: Mitsubishi Tanabe Pharma Corporation
Treatment for: Amyotrophic Lateral Sclerosis

Radicava ORS is a free radical scavenger indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Development Timeline for Radicava ORS

May 13, 2022Approval  FDA Approves Radicava ORS (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.